Vifor Pharma to propose Åsa Riisberg for appointment to Board of Directors
Vifor Pharma is pleased to announce that the Board of Directors will propose Åsa Riisberg for election to the Board at the Annual General Meeting on 6 May 2021.
Åsa Riisberg, a Swedish citizen, was formerly Partner and member of the extended Executive Committee of the private equity firm EQT. She has served on various international boards with current board seats at Atlas Antibodies, Netcompany, F-Secure, Dagens Nyheter, Bonnier News and Bonnier Capital as well as at the Women in Finance Foundation. Åsa is also an Advisory Board Member at the Stockholm School of Economics and member of the Investment Committee at Cinder Invest. She holds a M.Sc. in Financial Economics and Business Administration from Stockholm School of Economics.
Jacques Theurillat, Chairman of Vifor Pharma, commented: “We are very pleased that Åsa Riisberg will bring her expertise to the Board of Directors. Her broad knowledge and experience, particularly in the areas of investment management and operations are extremely valuable for Vifor Pharma. She will ideally complement the Board to assess the company’s business development and inorganic growth plans, aiming to become the global leader in iron deficiency, nephrology and cardio-renal therapies.”
Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is a partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma and Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care). Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).
For more information, please visit viforpharma.com .
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IPROOV29.7.2021 06:03:04 CEST | Press release
iProov Achieves Record-breaking Growth as Demand for Genuine Presence Assurance™ Soars
WEMADE29.7.2021 05:02:11 CEST | Press release
Wemade Co., Ltd. Announces Pre-Registration for MIR 4, an Open World K-Fantasy MMORPG
NY-RISKIFIED29.7.2021 01:59:08 CEST | Press release
Riskified Ltd. Announces Pricing of Initial Public Offering
NY-IFF28.7.2021 22:02:12 CEST | Press release
IFF Appoints Nicolas Mirzayantz President of IFF’s Nourish Division
MA-STILLA-TECHNOLOGIES28.7.2021 18:28:08 CEST | Press release
Stilla Launches Access Program for Industry’s First Six-Color Digital PCR System
Q428.7.2021 15:02:14 CEST | Press release
Q4 Helps Public Companies and Investment Firms Keep Their Teams Aligned and Informed
IL-ZS28.7.2021 15:02:04 CEST | Press release
ZS Elects Pratap Khedkar to CEO
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom